Heart Failure
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Aged between 18 and 80 years; (2) Meeting the diagnostic criteria for heart failure according to the latest international and national authoritative guidelines, including the following three categories of patients: HFrEF: heart failure with reduced ejection fraction, LVEF =50%, accompanied by diastolic dysfunction (e.g., E/e' >15); (3) Clear consciousness, able to understand the study procedures, capable of providing written informed consent, and demonstrating good treatment adherence.
Exclusion criteria
Exclusion criteria: (1) Age 80 years; (2) Patients with severe hepatic or renal dysfunction, malignancy, or severe infection; (3) Inability to obtain valid blood samples; (4) Pregnant or lactating women; (5) Individuals lacking legal capacity or with limited legal capacity, or any other condition deemed by the investigators to make participation in this clinical study inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All-cause mortality: death from any cause during the follow-up period.;Cardiovascular events: including heart failure rehospitalization (hospitalization due to worsening heart failure symptoms), acute myocardial infarction (meeting the Universal Definition of Myocardial Infarction), and stroke (imaging-confirmed ischemic or hemorrhagic stroke).; | — |
Secondary
| Measure | Time frame |
|---|---|
| Worsening of cardiac function: an increase of =1 class in New York Heart Association (NYHA) functional classification, or a decrease in left ventricular ejection fraction (LVEF) of =10% from baseline.;Drug responsiveness: therapeutic effects (e.g., symptom improvement, increase in LVEF) or adverse reactions (e.g., hypotension, deterioration of renal function) to heart failure medications such as ß-blockers or ACE inhibitors.; | — |
Countries
China
Contacts
Fuwai Hospital, Chinese Academy of Medical Sciences